CVM-1118 not checked
TaiRx, Inc. · TRX-818 · TRX-818 ER
FollowEvery change as it happens, and a Monday email
Trials
3 active
5 in total
Targets
—
None known yet
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Patients will initially receive CVM-1118 orally twice daily at 200 mg per dose (400 mg total daily dose). Patients who tolerate this dose for at least 2 Cycles will have the option of increasing the dose of CVM-1118 to 300 mg BID (600 mg total daily dose) if specific criteria are met.”In the company’s words, NCT03600233 on ClinicalTrials.gov
- Tested for
- Neuroendocrine Tumors, Pancreatic Neuroendocrine Tumor, Gastro-enteropancreatic Neuroendocrine Tumor, Lung Neuroendocrine Neoplasm, Neuroendocrine Carcinoma, Hepatocellular Carcinoma, Advanced Cancer, HCC - Hepatocellular Carcinoma
- Main trialPhase 2
- “CVM-1118 (TRX-818) is a new small molecule chemical entity being developed as a potential anti-cancer therapeutic by TaiRx, Inc. CVM-1118 is a potent anti-cancer agent in numerous human cancer cell lines. The safety of administrating CVM-1118 on human is evaluated from the phase 1 study. The objectives of the phase 2 study is to further investigate the efficacy of CVM-1118 for patients with advanced neuroendocrine tumors.”In the company’s words, NCT03600233 on ClinicalTrials.gov
- Other names
- TRX-818 · TRX-818 ER
Other drugs for Neuroendocrine Tumors
- CAM2029Camurus AB · Phase 3
- PembrolizumabMerck & Co. · Phase 3
- RYZ101RayzeBio, Inc. · Phase 3
- CemiplimabRegeneron · Phase 3
- DarovasertibIDEAYA Biosciences · Phase 3
- FianlimabRegeneron · Phase 3
Coming up2
- 31 DecPhase 2 trial completes · ClinicalTrials.gov
- 31 Dec 2027Phase 2 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials5
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 2Active, not recruiting | 30 Sep 2024 | Study of CVM-1118 for Patients With Advanced Neuroendocrine Tumors | |
| Phase 2Recruiting | 31 Dec 2026 | CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | |
| Phase 2Recruiting | 31 Dec 2027 | A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCC | |
| Phase 2Terminated | 16 Nov 2021 | CVM-1118 and Sorafenib Combination in Subjects With Advanced Hepatocellular Carcinoma | |
| Phase 1Completed | 8 Feb 2021 | Safety and Pharmacokinetic Study of CVM-1118 Extended-Release in Advanced Cancer Patients |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026